Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease

Tissue Antigens

Volumn 69, Issue 1, 2007, Pages 47-55

  Palikhe, A ^a,b   Sinisalo, J ^a   Seppanen M ^a   Valtonen, V ^a   Nieminen, M S ^a   Lokki, M L ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Complement C4; Coronary artery disease; HLA; LTA; MHC haplotype

Indexed keywords

COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; HLA A ANTIGEN; HLA B ANTIGEN; HLA B7 ANTIGEN; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOTOXIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEART TRANSPLANTATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; RISK; SMOKING HABIT; STATISTICAL SIGNIFICANCE;

ADULT; CORONARY ARTERIOSCLEROSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED;

EID: 33845910123     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00735.x     Document Type: Article

References (34)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005: 352: 1685-95.
2. Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002: 347: 1916-23.
3. Swanberg M, Lidman O, Padyukov L et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005: 37: 486-94.
4. The MHC sequencing Consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature 1999: 401: 921-3.
5. Porto I, Leone AM, Crea F, Andreotti F. Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. Cytokine 2005: 29: 187-96.
6. Yunis EJ, Larsen CE, Fernandez-Vina M et al. Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens 2003: 62: 1-20.
7. Reveille JD. Genetic studies in the rheumatic diseases: present status and implications for the future. J Rheumatol Suppl 2005: 72: 10-3.
8. Carrington M, OBrien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003: 54: 535-51.
9. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002: 32: 650-4.
10. Kramer J, Rajczy K, Hegyi L et al. C4B*Q0 allotype as risk factor for myocardial infarction. BMJ 1994: 309: 313-4.
11. Arason GJ, Kramer J, Bodvarsson S et al. Increased frequency of C4B null alleles in Icelandic patients with coronary disease. Mol Immunol 1998: 35: 412.
12. Szalai C, Fust G, Duba J et al. Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. J Med Genet 2002: 39: 46-51.
13. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994: 89: 2462-78.
14. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1994: 14: 840-56.
15. Sinisalo J, Mattila K, Valtonen V et al. Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002: 105: 1555-60.
16. Messer G, Spengler U, Jung MC et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991: 173: 209-19.
17. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens The Phillip Levine Award Lecture. Am J Clin Pathol 1978: 69: 103-20.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1215.
19. Marcus D, Alper CA. Methods for allotyping complement proteins. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology, 3rd ed. Washington, D.C.: American Society for Microbiology, 1986, 185-96.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001: 68: 978-89.
21. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003: 73: 1162-9.
22. Schneider S, Roessli D, Excoffier L. ARLEQUIN, version 2.000: A Software for Population Genetics Data Analysis, Geneva: University of Geneva, 2000.
23. Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Controlled Clin Trials 1997: 18: 274.
24. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002: 8: 1218-26.
25. Neri Serneri GG, Prisco D, Martini F et al. Acute T-cell activation is detectable in unstable angina. Circulation 1997: 95: 1806-12.
26. Falcone C, Campo I, Emanuele E et al. -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 2005: 354: 111-6.
27. Bucciarelli LG, Kaneko M, Ananthakrishnan R et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006: 113: 1226-34.
28. Siren MK, Sareneva H, Lokki ML, Koskimies S. Unique HLA antigen frequencies in the Finnish population. Tissue Antigens 1996: 48: 703-7.
29. Keso T, Perola M, Laippala P et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001: 154: 691-7.
30. Lee SH, Park SH, Min JK et al. Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 1997: 6: 603-9.
31. PROCARDIS Consortium. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet 2004: 12: 770-4.
32. Posch PE, Cruz I, Bradshaw D, Medhekar BA. Novel polymorphisms and the definition of promoter 'alleles' of the tumor necrosis factor and lymphotoxin alpha loci: inclusion in HLA haplotypes. Genes Immun 2003: 4: 547-58.
33. Nityanand S, Truedsson L, Mustafa A, Bergmark C, Lefvert AK. Circulating immune complexes and complement C4 null alleles in patients operated on for premature atherosclerotic peripheral vascular disease. J Clin Immunol 1999: 19: 406-13.
34. Arason GJ, Bodvarsson S, Sigurdarson ST et al. An age-associated decrease in the frequency of C4B*Q0 indicates that null alleles of complement may affect health or survival. Ann N Y Acad Sci 2003: 1010: 496-9.